This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
by Ahan Chakraborty
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
by Santanu Roy
AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks.
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
by Abhinab Dasgupta
Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
by Zacks Equity Research
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
3 Promising Genomics Stocks to Keep an Eye On in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
by Sundeep Ganoria
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
by Ekta Bagri
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
by Sundeep Ganoria
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
by Zacks Equity Research
Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%
by Zacks Equity Research
The consensus price target hints at a 398.3% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
by Sundeep Ganoria
CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
by Zacks Equity Research
Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.
3 Top Genomics Stocks to Add to Your Portfolio in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
by Zacks Equity Research
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
by Zacks Equity Research
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
by Zacks Equity Research
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
by Zacks Equity Research
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
by Zacks Equity Research
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
by Zacks Equity Research
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 12.70% and 14.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y
by Zacks Equity Research
PRGO reports mixed first-quarter 2025 results. The top line declines, largely due to the loss of sales stemming from exited businesses and product lines.
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
by Zacks Equity Research
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
by Zacks Equity Research
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.